Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
NCT ID: NCT03941626
Last Updated: 2021-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2019-09-01
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
NCT03638206
Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors
NCT02930993
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors
NCT04981691
Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
NCT03638193
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
NCT04008394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAR-T/TCR-T cells immunotherapy
Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
CAR-T/TCR-T cells immunotherapy
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAR-T/TCR-T cells immunotherapy
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patients aged 18 to 70 years .
3. Estimated survival of ≥ 12 weeks.
4. Pathological sections with positive expression of NY-ESO-1, Mesothelin, EGFRvIII and DR5 was confirmed by biopsy IHC test within 12 months.If NY-ESO-1 is positive expression ,positive HLAA\*0201 is required at the same time.
5. Solid tumor must have at least one measureable disease according to RECIST 1.1.
6. Routine blood test#hemoglobin\>=90 g/L; platelet\>=50×10\^9/L.
7. Liver function:ALT and AST≤2.5 times upper limits of normal (If the tumor infiltration is the main cause of abnormal liver function ,ALT and AST≤5 times upper limits of normal); bilirubin\<2.0 mg/dL.
8. Renal function:BUN: 9-20mg / dl; serum creatinine≤ 1.5 times upper limits of normal; endogenous creatinine clearance rate≥50 ml/min .
9. Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV.
10. Cardiac function: stable hemodynamic and left ventricular ejection fraction (LVEF)\>=55%.
11. ECOG score:0-1.
12. Adequate venous access for apheresis, and no other contraindications for leukapheresis .
13. Women of child-bearing age must have evidence of negative pregnancy test. Subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol.
14. Subjects with hypertension/diabetes must be stable blood pressure/blood glucose or ≤CTCAE 1 level 2 weeks before the screening.
In addition to the above criteria for inclusion, the following criteria shall be met according to the indications:
Patients with glioblastoma：
1. First disease progression or disease recurrence (≥ 1 cm and ≤ 5 cm) of a supratentorial WHO grade IV malignant glioma (GBM or gliosarcoma) based on imaging studies with measurable disease.
2. EGFRvIII, the target antigen, must be identified on tumor tissue by IHC or PCR, i.e. EGFRvIII positive via pathology report.
3. Insensitivity to chemoradiotherapy or chemoradiotherapy failure after operation molecular pathology.
4. Refused to receive radiotherapy or chemotherapy treatment.
Patients with liver cancer
1. DR5 or EGFRvIII positive via pathology report.
2. Untreatable by surgery ; Or postoperative recurrence ;Or no effective treatment.
3. Liver function：child-pugh A grade or child-pugh B grade.
Patients with gastric cancer
1. Mesothelin positive via pathology report.
2. The pathological stage：IIIA～IV.
3. chemoradiotherapy failure
4. Refused or unable to get surgery.
Patients with esophageal cancer
1. NY-ESO-1 positive via pathology report and HLA-A\*0201 positive in blood.
2. Refuse or unable to get surgery.
3. Postoperative recurrence or chemoradiotherapy failure.
Exclusion Criteria
2. malignant tumor cells with T cell origin via pathology test.
3. Organ failure: stage III or IV congestive heart failure; Renal failure and uremia; respiratory failure; disturbance of consciousness.
4. Acute or chronic GVHD after allogeneic hematopoiesis; Or being treated for GVHD; Or hormone or immunosuppressant used within 30 days
5. steroid hormoneswere used before and after blood collection and infusion
6. Patients with HIV infection or active hepatitis
7. Uncontrolled active infection.
8. Enrolled to other clinical study in the last 4 weeks.
9. Patients with systemic auto-immune disease or immunodeficiency.
10. Patients with neuropathy or psychosis, including dementia or epilepsy, or history of psychotropic substance abuse, or other substantial lesions that may increase central neurotoxicity.
11. Concomitant with the second tumor or other malignant tumors.
12. Patients with bone metastases are at risk of a pathological fracture resulting in paraplegia or life threatening.
13. Live attenuated vaccine was administered within 4 weeks prior to blood collection.
14. Blood oxygen saturation is maintained by oxygen inhalation.
15. Received major surgery within 2 weeks prior to screening ;Or Plan to receive surgery during study or within 2 weeks after injection.
16. Other patients that researchers considered unsuitable for inclusion.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henan Provincial People's Hospital
OTHER
Shenzhen BinDeBio Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019BDB016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.